Evidence map›Paper›PMID 30938438›Full record

ArticleThe Journal of infectious diseases2019

Disrupting Membrane Adaptation Restores In Vivo Efficacy of Antibiotics Against Multidrug-Resistant Enterococci and Potentiates Killing by Human Neutrophils.

Sandra Rincon, Diana Panesso, William R Miller, Kavindra V Singh, Melissa R Cruz, Ayesha Khan, An Q Dinh, Lorena Diaz, Rafael Rios, Yousif Shamoo and 4 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Sandra RinconCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Diana PanessoCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
William R MillerCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Kavindra V SinghCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Melissa R CruzDepartment of Microbiology and Molecular Genetics, UTHealth McGovern Medical School, Rice University.
Ayesha KhanCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
An Q DinhCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Lorena DiazCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Rafael RiosMolecular Genetics and Antimicrobial Resistance Unit and International Center for Microbial Genomics, Universidad El Bosque, Bogota, Colombia.
Yousif ShamooDepartment of Biosciences, Rice University.
Jinnethe ReyesCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Truc T TranCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Danielle A GarsinCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics, Rice University.
Rice University · USUniversidad El Bosque · COThe University of Texas Health Science Center at Houston · US

Funding

Defining Evolutionary Trajectories: Molecular adaptation to antibiotic resistanceR01AI080714 · NIAID · RICE UNIVERSITY · PI SHAMOO, YOUSIF · 2009 to 2023
$4.3M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
The Role of Reactive Oxygen Species in Mucosal Innate ImmunityR01AI076406 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2009 to 2019
$3.2M
Post-initiation regulatory mechanisms controlling ethanolamine utilizationR01AI110432 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A, WINKLER, WADE · 2015 to 2019
$2.2M
Molecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Molecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442k
Targeting Cell Membrane Adaptation in Multidrug-Resistant Enterococcus faeciumR21AI121519 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2017
$226k
NIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI076406NIAID NIH HHS R01 AI080714NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI110432NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI121519NIAID NIH HHS R21 AI143229
6 · The paper itself

Abstract

Daptomycin resistance in enterococci is often mediated by the LiaFSR system, which orchestrates the cell membrane stress response. Activation of LiaFSR through the response regulator LiaR generates major changes in cell membrane function and architecture (membrane adaptive response), permitting the organism to survive the antibiotic attack. Here, using a laboratory strain of Enterococcus faecalis, we developed a novel Caenorhabditis elegans model of daptomycin therapy and showed that disrupting LiaR-mediated cell membrane adaptation restores the in vivo activity of daptomycin. The LiaR effect was also seen in a clinical strain of daptomycin-resistant Enterococcus faecium, using a murine model of peritonitis. Furthermore, alteration of the cell membrane response increased the ability of human polymorphonuclear neutrophils to readily clear both E. faecalis and multidrug-resistant E. faecium. Our results provide proof of concept that targeting the cell membrane adaptive response restores the in vivo activity of antibiotics, prevents resistance, and enhances the ability of the innate immune system to kill infecting bacteria.

Indexed as

AnimalsAnti-Bacterial AgentsBacterial ProteinsCell MembraneDrug Resistance, Multiple, BacterialEnterococcus faecalisEnterococcus faeciumGram-Positive Bacterial InfectionsHumansMiceMicrobial Sensitivity TestsNeutrophilsAnti-Bacterial AgentsBacterial ProteinsCaenorhabditis elegansdaptomycinLiaRphagocytosisPMNs

Identifiers

PMID30938438
PMCPMC6603970
OpenAlexW2929592692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.